NCT07436689Phase 3Enrolling by invitation

Long-Term Open-Label Extension Study of Oral Levosimendan

Study sponsor: Tenax Therapeutics, Inc. · TENX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-03Estimated

Enrollment · participants800Estimated

Source updated2026-09-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pulmonary Hypertension Associated With HFpEF

Treatments or interventions studied

TNX-103Drug

Primary outcomes · main study measures

measure: The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEs; description: The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEs will be tabulated by system organ class and preferred term.; timeFrame: From enrollment through study completion (up to 3 years)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history